External control arm registry for non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry collects current and future clinical data from adults with pathologically confirmed non-small cell lung cancer to create external control arms. Data collected may include demographics, treatment history, imaging, performance status, and outcomes from participating clinical sites and registries. Eligible participants are adults (≥18) with confirmed NSCLC who are fit for further systemic therapy within the specified treatment window and able to consent, while exclusions include inability to consent or concurrent enrollment in an investigational treatment trial. The assembled external control cohorts are intended to support more meaningful comparisons against patients receiving new therapies or enrolled in interventional studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. \> 18 years of age at the time of informed consent
2. Pathologically confirmed locally advanced or metastatic NSCLC
3. ECOG Performance of less than or equal to 1 within 4 weeks prior to starting index therapy.
4. Life expectancy of more than 3 months
5. Able to understand and sign informed consent
6. Evidence of measurable disease (as assessed by the Investigator) on available imaging (e.g CT, MRI, PET)

\*see protocol for cohort specific inclusion criteria\*

Exclusion Criteria:

1. Actively on a clinical trial of an investigational agent
2. Currently receiving active systemic therapy for another malignancy
3. Eligible for treatment with curative intent

\*see protocol for cohort specific exclusion criteria\*

Where it's running

• Pacific Cancer Care
  Monterey, California, United States Recruiting
• Bayhealth Medical Center, Kent Campus
  Dover, Delaware, United States Recruiting
• Bayhealth Medical Center- Sussex Campus
  Milford, Delaware, United States Recruiting
• Northwest Oncology and Hematology
  Barrington, Illinois, United States Recruiting
• Northwest Oncology and Hematology
  Elk Grove, Illinois, United States Recruiting
• Northwest Oncology and Hematology
  Hoffman Estates, Illinois, United States Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.